HC Wainwright Forecasts Edap Tms FY2030 Earnings

Edap Tms S.A. (NASDAQ:EDAP) – Research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Edap Tms in a research note issued to investors on Thursday, April 9th. HC Wainwright analyst S. Ramakanth expects that the medical equipment provider will earn $0.12 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Edap Tms’ current full-year earnings is ($0.60) per share.

Edap Tms (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). The business had revenue of $22.22 million during the quarter, compared to the consensus estimate of $21.28 million. Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edap Tms in a research report on Monday, December 29th. Wall Street Zen downgraded Edap Tms from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Edap Tms Stock Performance

NASDAQ EDAP opened at $3.30 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a market cap of $123.39 million, a price-to-earnings ratio of -4.29 and a beta of -0.09. Edap Tms has a twelve month low of $1.21 and a twelve month high of $5.05. The business has a 50-day moving average price of $4.11 and a 200-day moving average price of $3.22.

Institutional Investors Weigh In On Edap Tms

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EDAP. Flax Pond Capital LLC purchased a new stake in Edap Tms during the fourth quarter valued at approximately $2,623,000. Leonteq Securities AG purchased a new stake in Edap Tms during the fourth quarter valued at approximately $313,000. Rock Springs Capital Management LP raised its position in Edap Tms by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock valued at $4,233,000 after purchasing an additional 16,500 shares during the period. Kovack Advisors Inc. purchased a new stake in Edap Tms during the fourth quarter valued at approximately $53,000. Finally, Financial Planning Navigators CORP purchased a new stake in Edap Tms during the fourth quarter valued at approximately $33,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.